LBL-007 (anti-LAG3 monoclonal antibody):
“Characterization of a novel anti-human lymphocyte activation gene 3 (LAG-3) antibody for cancer immunotherapy”. 发表于 MABS 2019 (论文)。
LBL-024：a bispecific antibody:
“An anti-PD-L1 and 4-1BB bispecific antibody with highly differentiated binding affinity, shows anti-tumor efficacy in a mouse tumor model” 被2021-AACR接受为墙报
LBL-015：a bispecific fusion protein：
“A novel anti-PD-1 fused with TGF-βR2, shows a great anti-tumor activity in a mouse MC38 model” 被2021-AACR接受为墙报
LBL-007 (anti-LAG3 monoclonal antibody):
“Phase I study of LBL-007, a novel anti-human lymphocyte activation gene 3 (LAG-3) antibody in patients with advanced solid tumors” 被2021-ASCO接受为墙报
LBL-019 (anti-TNFR2 monoclonal antibody) :
“LBL-019, a novel anti-TNFR2 antibody, shows a potent anti-tumor efficacy in a mouse MC38 model” 被2022 AACR接受为墙报
